Stewart takes responsibility for maximising the value of Amarin’s lead product, AMR101, a new drug currently in Phase 3 clinical trials for the treatment of high triglycerides. The company has also completed enrolment to its Phase 3 Marine trial earlier than expected, with results now due early next year.
Stewart has more than 30 years of experience in the pharmaceutical industry, including five as ceo of CollaGenex Pharmaceuticals. He also worked for the ASTA Medica Group, where for 10 years he managed several business units in the US and internationally. He began his career in sales and marketing for Winthrop Laboratories, in the UK, and subsequently held a number of positions of increasing responsibility within the Sterling-Winthrop Group.
Declan Doogan, who has been the company’s interim ceo, will continue to support Amarin as chief medical officer for the majority of his time.
Amarin names Colin Stewart as president and ceo
Has been in the pharmaceutical industry for more than 30 years
You may also like
Research & Development
Dual inhibition of motor proteins KIF18A and CENP-E shown to selectively kill cancer cells
Researchers from Osaka University and MIT have discovered that blocking two cooperative motor proteins involved in chromosome alignment can trigger cancer cell death, revealing a promising new target for anticancer therapies
Research & Development
Samsung Epis launches subsidiary Epis NexLab for next-gen biotech platform development
Epis NexLab will focus on transforming highly scalable peptide-related technologies into development platforms for the discovery of new drug candidates, including license-out or joint development with global pharmaceutical companies